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Abstract
Machado-Joseph disease (MJD) or spinocerebellar ataxia type 3 (SCA3) is an autosomal dominantly-inherited
neurodegenerative disorder caused by the over-repetition of a CAG codon in the MJD1 gene. This expansion translates
into a polyglutamine tract that confers a toxic gain-of-function to the mutant protein – ataxin-3, leading to
neurodegeneration in specific brain regions, with particular severity in the cerebellum. No treatment able to modify the
disease progression is available. However, gene silencing by RNA interference has shown promising results. Therefore, in
this study we investigated whether lentiviral-mediated allele-specific silencing of the mutant ataxin-3 gene, after disease
onset, would rescue the motor behavior deficits and neuropathological features in a severely impaired transgenic mouse
model of MJD. For this purpose, we injected lentiviral vectors encoding allele-specific silencing-sequences (shAtx3) into the
cerebellum of diseased transgenic mice expressing the targeted C-variant of mutant ataxin-3 present in 70% of MJD
patients. This variation permits to discriminate between the wild-type and mutant forms, maintaining the normal function
of the wild-type allele and silencing only the mutant form. Quantitative analysis of rotarod performance, footprint and
activity patterns revealed significant and robust alleviation of gait, balance (average 3-fold increase of rotarod test time),
locomotor and exploratory activity impairments in shAtx3-injected mice, as compared to control ones injected with shGFP.
An important improvement of neuropathology was also observed, regarding the number of intranuclear inclusions,
calbindin and DARPP-32 immunoreactivity, fluorojade B and Golgi staining and molecular and granular layers thickness.
These data demonstrate for the first time the efficacy of gene silencing in blocking the MJD-associated motor-behavior and
neuropathological abnormalities after the onset of the disease, supporting the use of this strategy for therapy of MJD.
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Introduction
Machado-Joseph disease (MJD), also designated spinocerebellar
ataxia type 3 (SCA3), is the most common dominantly-inherited
cerebellar ataxia worldwide [1–4]. It is part of a group of nine
known polyglutamine (polyQ) disorders which share expanded
CAG repeat mutations that translate into polyQ tracts [5,6]. The
signs and symptoms of MJD include progressive postural
instability, gait and limb ataxia, weight loss and, in severe cases,
premature death [2,7,8]. The pathology of MJD includes severe
neuronal loss in the spinal cord and selective brain regions such as
dentate nuclei (cerebellum), pontine nuclei (brainstem), substantia
nigra, and striatum [2,7–10]. MJD is caused by ataxin-3 carrying a
stretch of 54–84 consecutive glutamines (mutant ataxin-3) in
opposition to normal ataxin-3 whose glutaminic stretch has 14–37
repetitions [11,12]. The polyQ expansion confers a toxic gain-of-
function to the mutant protein, leading to the formation of
neuronal intranuclear inclusions, neuronal dysfunction and
degeneration [13].
Several therapeutic strategies are under study for MJD
treatment such as modulation of Ca2+ signalling, inhibition of
calpain-mediated proteolysis of mutant ataxin-3 in the brain or
promotion of degradation of mutant ataxin-3 species, either by
activation of the proteasome or of the beclin-1 autophagy pathway
[14–17]. Although such approaches offer promise, the most direct
solution to block the pathogenesis of MJD would be to prevent the
translation of the mutant ataxin-3 protein in the brain. Accord-
ingly, in conditional transgenic MJD, HD and SCA1 mice shutting
off expression of the mutant transgene dramatically slows disease
progression and, for selected features, even reverses severe diseases
pathology [18,19].
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Decreasing the expression of mutant protein can be achieved by
using the RNA interference (RNAi) mechanism to inhibit the
expression of the target gene. RNAi-based strategies have been
used to supress the expression of toxic polyQ proteins in transgenic
mouse models of the polyQ disorders SCA1 and Huntington’s
disease [20–23]. This approach has been refined to discriminate
between the wild-type and mutant forms of the messenger RNA by
developing silencing sequences targeting single nucleotide poly-
morphisms (SNP) [24]. In MJD patients, an intragenic single
nucleotide polymorphism (SNP) at the 39 end of the CAG tract of
the ataxin-3 gene is present in more than 70% of the cases [25].
This SNP can be used to selectively inactivate mutant ataxin-3,
significantly decreasing the severity of the neuropathological
abnormalities associated with concomitant induction of MJD, as
we previously showed in a (LV)-based rat model of MJD [26].
Nevertheless, no study has ever evaluated the efficacy of gene
silencing in a) a transgenic mouse model of MJD, b) exihibiting a
severe phenotype, c) regarding motor behavior impairments,
d) when initiated after disease onset.
Therefore, in the present study we used lentiviral vectors (LV)
encoding short-hairpin RNAs (shRNAs) targeting this SNP, to
downregulate mutant ataxin-3 in the cerebellum of a transgenic
MJD mouse model that exhibits an early and very severe motor
and neuropathological phenotype [15]. This model was generated
in a C57/BL6 background, by the introduction of a truncated
form of human ataxin-3 with 69 repeats [15,27] and encoding the
C variant of the human ataxin-3 transgene sequence that is present
in 70% of the MJD patients [15,25,28], making this model
particularly adequate for the allele-specific silencing here per-
formed. Transgenic mice expressing a truncated form of the
mutant protein have also been used for investigation of gene
silencing approaches in Huntington’s disease [21,29]. Moreover,
this MJD model displays robust ataxic behavior and neuropath-
ological features from 21 days of age, which makes it time and
cost-effective, and mimics a late stage of disease.
In this work we show for the first time that allele-specific
silencing of mutant ataxin-3, even when initiated at a late stage of
disease dramatically improves motor coordination and reduces
neuropathological abnormalities related with MJD.
Results
Allele-specific silencing reduces mutant ataxin-3 protein
levels and the number of intranuclear inclusions
The polyQ expansion in mutant ataxin-3 confers aggregation
properties to the mutant protein, leading to the formation of
neuronal intranuclear inclusions, which despite its unclear role in
the disease process are a hallmark of MJD [13]. We investigated if
specific silencing would reduce the number of aggregates in the
cerebellum, a region that is particularly involved in MJD, in a
transgenic mouse model of MJD with particular expression of
mutant ataxin-3 in Purkinje cells [15]. These transgenic mice were
generated using the human ataxin-3 sequence [15] with a
polymorphism that is present in 70% of MJD patients [25,28],
which permitted the design of a shRNA that specifically targets
mutant ataxin-3 [26]. Therefore, we injected transgenic mice at 3
weeks of age (P21–25) with LV encoding the allele-specific
silencing sequence for the human ataxin-3 (shAtx3) or a control
sequence (shGFP), see Figure S1. Preliminary experiments in this
transgenic model showed that a single injection of 6 ml of lentiviral
vectors encoding GFP (n=8) mediated an extensive transduction
(around 60%) of the cerebellar cortex (Figure S2 and Figure S3).
In the shGFP-injected mice cerebella, we found increased
ataxin-3 immunoreactivity in aggregated inclusions (Fig. 1A–F), as
compared to shAtx3-injected mice which displayed a diffuse
subcellular distribution of ataxin-3 in the cytoplasm of the Purkinje
cells (Fig. 1G–L). Importantly, the number of inclusions was
robustly and significantly decreased in mice injected with the
silencing vectors (shAtx3) as compared to the control ones (n=6;
4.3060.07 versus 19.560.5 nuclear aggregates per 100 Purkinje
cells, P=0.0018; Fig. 1M). Further analysis revealed that mice
injected with the control vectors encoding the short-hairpin
targeting GFP (shGFP) exhibit ataxin-3 aggregates (HA tag) that
co-localize with the co-expressed LacZ reporter gene; whereas
aggregates from mice injected with vectors encoding the short-
hairpin against mutant ataxin-3 (shAtx3) do not co-localize with
LacZ and therefore correspond to non-transduced cells (Figure
S4). This indicates that expression of the shRNAs against mutant
ataxin-3 but not the control sequences prevented formation of
ataxin-3 aggregates in the transduced cells. We further investigated
the effects of mutant ataxin-3 silencing by western blot analysis of
protein levels in the transgenic mice cerebella (Fig. 2A). Probing
the membrane with the 1C2 antibody, a marker of the
polyglutamine-expanded proteins, revealed a significant decrease
in the levels of oligomerized and aggregated ataxin-3 in transgenic
mice injected with shAtx3 vectors compared to the control mice
injected with shGFP vectors (n=3; aggregates at the upper level of
the running and stacking gels Fig. 2B, 2D: 0.4460.03 versus
0.5760.03 in control, P=0.0023, normalizing with actin;
0.4060.02 versus 0.5160.01 in control, P=0.0028, normalizing
with lacZ; and oligomers Fig. 2C, 2E: 3.6660.17 versus
4.9660.29 in control, P=0.018 normalizing with actin;
2.3260.21 versus 3.0660.14 in control, P=0.04, normalizing
with lacZ).
Silencing of mutant ataxin-3 preserves Purkinje cells
integrity and molecular and granular layer thickness in
the cerebellar cortex
Purkinje cells are key and vulnerable elements regulating the
cerebellar function. Therefore we analyzed if silencing mutant
ataxin-3 would prevent loss of Purkinje cell markers immunore-
activity and degeneration as well as neurons from molecular and
granular layers. Control mice (shGFP) exhibited reduced calbindin
immunoreactivity of Purkinje cells (Fig. 3A, C), which was robustly
and significantly preserved in mice injected with shAtx3 (Fig. 3B,
D, G: n=6; 3.06060.546 versus 0.85260.079 in control,
P=0.0026). Similarly, silencing mutant ataxin-3 prevented loss
of DARPP-32 immunoreactivity (Figure S5).
The cerebellar cortex is characterized by strong cellular
interconnectivity, which may propagate the degeneration of one
cell to the other. Cresyl violet staining (Fig. 3E, F) revealed that the
thickness of the molecular and granular layers were significantly
larger in mice injected with shAtx3 as compared to control mice,
which suggests a prevention of neurodegeneration (Fig. 3H;
molecular layer: n=6; 111.167.14 mm versus 67.3263.08 mm in
control, P=0.0005; Fig. 3I; granular layer: n=6; 107.262.43 mm
versus 77.664.42 mm in control, P=0.0004). Furthermore,
FluoroJade-B staining, revealed a consistently increased staining
suggestive of increased neuronal degeneration in control mice
(Fig. 4J), as compared to mice injected with shAtx3 (Fig. 4K).
Finnally, Golgi staining revealed reduced arborization in the
molecular layer of shGFP-injected mice (Fig. 4L), as compared to
mice injected with shAtx3 silencing sequences (Fig. 4M).
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Silencing of mutant ataxin-3 alleviates balance and
motor coordination impairments in the MJD transgenic
mouse
In order to evaluate whether gene silencing would alleviate gait
and limb ataxia the MJD transgenic mice used in this study [15],
stereotaxicaly injected with the silencing shAtax3 vectors, were
submitted to behavior testing every two weeks until ten weeks post-
injection (Figure S6 A). Already at the time of injection, at 21–25
days old, the animals displayed a marked phenotype characterized
by an ataxic movement and difficulty to walk and to equilibrate.
At the first test performed before the stereotaxic injection, animals
barely stayed in the rotarod for 5 seconds, and, throughout the
study time course, control mice (injected with shGFP) exhibited
drastic impairment in the rotarod task. Silencing of the mutant
ataxin-3 robustly enhanced the rotarod performance with mice
consistently exhibiting better performances than mice injected
with shGFP. These differences were significant and robust from 4
weeks after the injection at constant rotarod velocity (Fig. 4A;
n=8; shAtx3 55.569.4 s versus shGFP 11.9262.1 s; P,0.001)
and in the accelerated test (Fig. 4B; n=8; shAtx3 39.9363.8 s
versus shGFP 17.5264.59 s; P,0.001), and were maintained
Figure 1. Allele-specific silencing of mutant ataxin-3 reduces
the number of intranuclear inclusions. A–L) Confocal analysis of
mutant ataxin-3 aggregates in the Purkinje cells at 10 weeks post-
injection. Transgenic MJD mice injected at 21–25 days of age with
shGFP (control) display intranuclear inclusions of mutant ataxin-3
(revealed by immunohistochemistry with an HA antibody) in Purkinje
cells (revealed by calbindin immunohistochemistry) versus a diffuse
expression of mutant ataxin-3 in mice injected with the silencing
shAtx3. M) The number of intranuclear inclusions is significantly
reduced in transgenic mice injected with shAtx3 compared to control
animals injected with shGFP (n=6, ***P,0.001; Unpaired Student’s
t-test).
doi:10.1371/journal.pone.0052396.g001
Figure 2. Allele-specific silencing of mutant ataxin-3 reduces
the levels of mutant aggregated protein. A) Western blot analysis
of cerebellar lysates stained with 1C2 antibody (for the polyglutamine
expansion). Differences in levels of high molecular weight protein
species were detected between transgenic mice injected with shAtx3
(n= 3) and animals injected with shGFP (n= 3). Normalization of protein
levels was made with b-actin protein endogenous levels, and with b-gal
marker (reporter gene of shRNAs lentiviral vector). B, D). The
quantification of aggregated protein levels (in the stacking gel)
revealed significant differences between transgenic mice injected with
shAtx3 and control animals injected with shGFP (n= 3; *P,0.05;
Unpaired Student’s t-test). C,E). Oligomerized species were also
significantly reduced in animals injected with shAtx3 compared to
control animals (n= 3; *P,0.05; Unpaired Student’s t-test).
doi:10.1371/journal.pone.0052396.g002
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along the experiment time course (Fig. 4A, B; n=8; 10 weeks;
constant: shAtx3 61.95611.9 s, and shGFP 19.2564.1 s; acceler-
ated: shAtx3 44.9265.72 s, and shGFP 24.264.02 s). This
improvement in motor functions of mice injected with shAtx3
was further investigated by analysis of the footprint patterns. From
4 weeks post-injection mice injected with shAtx3 showed a
consistently larger stride length (Fig. 4C) than mice injected with
shGFP, a difference that was significant from 6 weeks on (n=8;
P,0.01), until the end of the experiment at 10 weeks post-
injection (n=8; P,0.01). A similar pattern and an even more
robust effect was registered upon analysis of the footprint overlap
(Fig. 4D), where mice injected with shAtx3 revealed a significantly
better overlap measure since 6 weeks after the injection compared
to control mice (n=8; P,0.001). Another quantitative parameter,
the hindbase width of footprint patterns confirmed the improved
motor performance of shAtx3-injected mice (Figure S6 B).
Figure 3. Silencing mutant ataxin-3 reduces Purkinje cell pathology, and prevents neurodegeneration and shrinkage of cellular
layers within the cerebellar cortex. A–D) Fluorescence microscopy analysis of calbindin revealed a loss of dentritic arborizations and a shrinkage
of Purkinje cells in the mice injected with shGFP (n= 8) compared to control mice injected with shAtx3 (n= 8). G) Quantification of optical
densitometry of calbindin immunoreactivity. Silencing of mutant ataxin-3 preserved immunoreactivity for calbindin in the shAtx3-injected mice as
compared to control mice (n = 6; **P,0.01; Unpaired Student’s t-test). E–F) Cresyl violet staining. A more severe loss of neurons was observed in the
control mice (shGFP, n= 8) as compared to mice injected with shAtx3. H–I) paralleled by a significant decrease in the size of the molecular (ML) and
granular layers (GL) in control mice as compared to shAtx3-injected mice. *Statistical significance (n=6; ***P,0.01; Unpaired Student’s t-test). J–K)
Fluorojade-B staining. Degenerating fluorescently-labelled neurons were only observed in control mice (shGFP, n=8), while no degeneration was
observed in mice injected with shAtx3 (n=8). L–M) Golgi staining. A reduction in the number of dentritic arborizations in the molecular layer was
observed in mice injected with shGFP (n= 8) compared to a higher density of arborizations detected in mice injected with shAtx (n=8). The figure
shows representative images that were reproducible among the different groups of animals.
doi:10.1371/journal.pone.0052396.g003
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Silencing of mutant ataxin-3 enhances locomotor and
exploratory activities and reduces anxiety in the MJD
transgenic mice
We further analyzed the locomotor activity every two weeks
after transduction of mice cerebella by monitoring behavior in an
activity box for 30 minutes, after a 10 minutes period of
habituation. Animals injected with shAtx3 (n=8) exhibited
increased movement as compared to shGFP-injected mice (n=8;
Fig. 5A). These differences revealed that animals injected with
shAtx3 consistently traveled longer distances than control mice
(Fig. 5B; n=8; 6 weeks, P,0.05; and 8 weeks, P,0.01), exhibited
an increase in medium velocity (Fig. 5C), and maximum velocity
of movement (Figure S6 C). Analysis of the first 10 minutes in the
activity box at 10 weeks post-injection also revealed that mice
injected with shAtx3 traveled a longer distance in the first
10 minutes as compared to control mice, revealing an increase in
the exploratory behavior (Figure S6 D). Furthermore, when the
arena was divided in two zones, it became clear that shAtx3-
injected mice traveled a longer distance in zone 1 (Fig. 5D). Also,
the control animals (shGFP-injected) traveled to the center of the
cage significantly less often than shAtx3-injected mice, suggesting
that these latter animals were less anxious (Fig. 5E). In fact, when
the total distance or the number of entries in zone 2 was
normalized with the total distance, the animals injected with
shAtx3 exhibited a less anxious behavior, comparing to control
mice shGFP-injected (Fig. 5GF, G).
Discussion
In this study we show for the first time that allele-specific
silencing of mutant ataxin-3 with lentiviral vectors robustly rescues
Machado-Joseph disease behavioral and neuropathological phe-
notype in a severely affected transgenic mouse model.
We previously showed that allele-specific silencing of mutant
ataxin-3 expression could mitigate MJD neuropathology induced
by viral-mediated expression of mutant ataxin-3 in the rat striatum
[26]. In the present work we addressed the question whether this
strategy would rescue behavioral and neuropathological impair-
ments, when applied in the cerebellum of a transgenic mouse
model already presenting a severe MJD-associated phenotype at
the time of viral injection [15]. The transgenic mouse model here
used was particularly suited for this purpose as it encoded the
human C variant of the human ataxin-3 transgene sequence that is
present in 70% of the MJD patients, which allowed allele-specific
gene silencing. Moreover, this model encodes a truncated mutant
ataxin-3 that induces the strong phenotype that would typically be
found in a clinical setting at the time of intervention. Transgenic
mouse models expressing truncated forms of the protein have been
extensively used to model polyglutamine disorders such as
Huntington’s disease [21,29]. In contrast to some of the MJD
transgenic mice expressing full-length ataxin-3 developed in the
last years [30–36], whose behavioral and neuropathological
deficits are mild and develop after several months of age, the
use of a truncated form of ataxin-3 leads to an early and severe
MJD phenotype with robust abnormal neuropathological and
Figure 4. Silencing mutant ataxin-3 improves balance and motor coordination in transgenic MJD mice. A–B) Rotarod performance. Mice
injected at 21–25 days of age with shAtx3 (n=8) exhibited a significant better performance in constant velocity (5 r.p.m.) and accelerated rotarod,
compared to control mice (shGFP, n= 8) from 4 weeks after the injection. C–D) Footprints patterns quantitative analysis, revealed a significantly
better motor coordination in mice injected with shAtx3 (n= 8) from 6 weeks post-injection compared to control ones (shGFP, n=8), with a higher
stride length and a better footprint overlap. *Statistical significance (**P,0.01; ***P,0.001; 2-way ANOVA, Bonferonni post-hoc test).
doi:10.1371/journal.pone.0052396.g004
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behavior deficits while maintaining physiological relevance for this
particular question [15,37].
Gene silencing has been successfully used to downregulate the
expression of mutant genes and to rescue phenotypes in various
neurodegenerative diseases [21–23,38–40]. However, a potential
risk of gene silencing lacking discrimination between normal and
mutant forms of the causative protein is the loss of the normal
protein function. While for some diseases such silencing may not
Figure 5. Allele specific silencing of mutant ataxin-3 improves exploratory and locomotor activity and reduces anxiety in MJD
transgenic mice. A) Representative plots of moved track at 10 weeks post-injection during 40 minutes in the activity box. Animals injected with
shAtx3 (n= 8) traveled more that shGFP-injected mice (n=8). The figure shows representative images that were reproducible among the different
groups of animals. B–C) Locomotor horizontal activity of mice was tracked for 30 minutes (after a 10 minutes habituation period), and revealed a
significantly better locomotor activity of mice injected with shAtx3 (n=8) as compared to control mice (shGFP, n= 8), by traveling longer distances
with a higher medium velocity. D–E) Two zones analysis of exploratory behavior, revealed that shAtx3-injected mice (n=8) had increased exploratory
behavior and were significantly less anxious than controls (shGFP; n=8). F–G) This reduced anxiety of shAtx3-injected mice was confirmed through
analyzis of the distance in zone two normalized with the overall distance in the arena, and also the number of entries in zone 2 normalized with the
overall distance in the arena. *Statistical significance (*P,0.05; **P,0.01; ***P,0.001; 2-way ANOVA, Bonferonni post-hoc test).
doi:10.1371/journal.pone.0052396.g005
RNAi Silencing of Machado-Joseph Disease
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present any drawback [29], for other disorders it is unlikely that
the loss of normal protein function would be tolerated. Even
though no degenerative phenotype was observed either in a MJD
knockout animal [41] or upon non-specific gene silencing in a
lentiviral rat model [10], absence of ataxin-3 has been reported to
mediate cytoskeletal disorganization and increase cell death in
cellular lines [42]. Therefore it may be prudent to either avoid
complete silencing of the targeted protein or to employ allele-
specific approaches able to preserve the wild-type protein as used
in this study. We previously reported that a shRNA allele-specific
lentiviral vector permitted selective silencing of mutant ataxin-3 in
the striatum, while preserving wild-type ataxin-3, by targeting a C
variant of the human ataxin-3 sequence that is present in 70% of
the MJD patients [26]. Specific silencing in cellular models has
also been reported to SNPs targeting ataxin-7 in SCA7 [43] and
huntingtin in Huntington’s disease [44,45]. In the present work,
we knocked-down the mutant ataxin-3 transgene carrying the C-
polymorphism present in the transgenic animal here used with the
previously generated lentiviral vectors encoding an allele-specific
shRNA. As there is no homology between mouse ataxin-3 and
human ataxin-3 in the region targeted by the silencing sequence
(See Fig. S1C), this means that the shRNA used in this study was
specific only to human ataxin-3 and therefore does not allow to
further infer about the selectivity of the approach, which had been
previously demonstrated. Nevertheless, it shows that this allele-
specific sequence is highly effective, mediating strong knock-down
of the mutant ataxin-3 transgene in the cerebellum and rescuing
motor impairments and neuropathology in a severe MJD model,
even when initiated at late stage of disease. To our knowledge this
is the first demonstration of alleviation of neuropathology and
ataxia upon gene transfer of an allele-specific silencing sequence to
the mouse cerebellum.
The cerebellum plays an important role in motor coordination
and motor learning [46]. Damage of the cerebellum causes motor
coordination problems such as gait and limb ataxia that partially
explain the disabling clinical features of MJD, as this is one of the
most affected regions in the disorder [2,8]. The MJD transgenic
mouse used in this study [15], exhibits mutant ataxin-3
preferential expression in Purkinje cells of the cerebellar cortex,
a marked atrophy of the cerebellum already at 3 weeks of age, and
pronounced ataxic motor behavior. Similarly, motor incoordina-
tion and ataxia development related with progressive Purkinje
neuron dendritic and somatic atrophy have been reported in
SCA1 transgenic mice [47]. In this study we show that allele-
specific silencing of mutant ataxin-3 mediates preservation of
dendritic arborizations and Purkinje cells that project into the
molecular layer. This may presumably underlie the improved
motor performance of animals transduced with shAtx3 as
compared to control ones.
The different cell types in the cerebellum are strongly
interconnected to each other, and degeneration of one type can
lead to atrophy of the interconnected cells. Purkinje cells account
for a large fraction of the molecular layer thickness and its atrophy
in aging has been associated with a reduction in dendritic
arborizations of Purkinje cells [48,49]. The preservation of
Purkinje cells in mice injected with shAtx3 may therefore explain
the larger molecular layer thickness in these mice, while Purkinje
cell degeneration in control animals probably induces shrinkage of
the molecular layer.
Interestingly, in MJD patients the cerebellar cortex and the
Purkinje layer are initially relatively preserved, in contrast to other
spinocerebellar ataxia such as SCA1 and SCA2 [50]. Instead,
neuronal degeneration affects initially dentate nucleus neurons,
displaying grumose degeneration [50]. However, as pathology
progresses Purkinje cells dysfunction and degeneration develops in
MJD mice and patients [51,52], which may contribute to the
retrograde atrophy of cells from molecular and granular layer.
Degeneration of Purkinje cells may reduce directly the information
input, reduce afferent efficacy, and affect information integration
and signal transmission, consequently leading to a reduction in
overall cerebellar function. Thus, mutant ataxin-3 silencing in
Purkinje cells and other cells in the cerebellar cortex, may prevent
the neurodegeneration and cell death in MJD affected regions of
the cerebellum. However, translation of this approach to the clinic
may have higher chances of success if also targeting the deep
cerebellar nuclei, the region with primary degeneration in MJD.
The number of mutant ataxin-3 nuclear inclusions was also
significantly reduced in mice injected with shAtx3, as previously
observed in the lentiviral-based model [26], in parallel with a
subcellular diffuse distribution of the protein in the cytoplasm. The
presence of ataxin-3 in the nucleus has been shown to drastically
aggravate the pathology in Machado-Joseph disease [32]. There-
fore, silencing mutant ataxin-3 may prevent nuclear accumulation
and degeneration contributing to preservation of neuronal
function and motor behavior of mice injected with shAtx3.
The rotarod test for motor performance is a valid indicator of
progressive ataxia; evidentiating proper foot placement and
coordination in response to the rotating rod challenges the
cerebellum. The allele-specific silencing of mutant ataxin-3 greatly
improved the rotarod performance from 4 weeks after the
injection, allowing animals to equilibrate in the rotarod for more
than 60 seconds, on average 3-fold the time found for control
mice. Even though this performance is far from the one that is
commonly found in wild-type mice (around 120 s), it corresponds
to a very robust preservation of performance. Footprints analysis
and activity measures also revealed that mutant ataxin-3 silencing
strongly alleviates the phenotype of the MJD transgenic mice. In
other polyglutamine disorders silencing of mutant protein also
reduced the neurological abnormalities [20–22]. Nevertheless,
improvement in the rotarod performance upon mutant protein
silencing did exceed 0.5 to 1-fold compared to the controls
[20,21].
Our data suggest that shRNA specific silencing reduces the
neuropathology and the motor behavior deficits of a severely
impaired transgenic MJD mouse model. These results suggest that
this approach is a promising therapeutic strategy to MJD patients.
Importantly, several questions should be addressed, from the
shRNAs long-term safety, to the precise brain regions to be
targeted.
Materials and Methods
Lentiviral vectors
Viral vectors encoding a short-hairpin targeting the mutant
ataxin-3 and the GFP, with the LacZ reporter gene (26) were
produced described previously [53].
In vivo experiments
Animals. MJD transgenic mice (C57BL/6 background)
expressing the N-terminal-truncated human ataxin-3 with 69
glutamine repeats and an N-terminal hemagglutinin (HA) epitope
driven specifically in cerebellar Purkinje cells by the L7 promoter
were maintained at CNC by backcrossing heterozygous males with
C57BL/6 females [15,54]. The present study used 8 heterozygous
females and 8 heterozygous males injected with lentiviral vectors
(in two separate cohorts, with 4 animals per group in each one)
encoding the short-hairpin targeting the mutant ataxin-3 (shAtx3;
n=8), and as control the short hairpin targeting the GFP (shGFP;
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n=8). Behavioral testing began at 21–25 days of age (P21–25), and
one day after the first behavioral testing animals were submitted to
stereotaxic surgery. The experiments were carried out in
accordance with the European Community Council directive
(86/609/EEC) for the care and use of laboratory animals.
Stereotaxic injection of lentiviral vectors
The animals (P21–25) received a single 6 ml injection of LV
(200 000 ng of p24/ml), at 0.25 ml/min at the coordinates:
21.6 mm rostral to lambda, 0 mm midline, and 1 mm ventral
to the skull surface, with the mouth bar set at 23.3.
Behavioral testing
Mice were trained on a battery of motor tests starting at 21–25
days of age (P21–25) and performed every 2 weeks until 10 weeks
by an experienced operator in a blind fashion way. All tests were
performed in the same dark room after 30 minutes of acclima-
tization. Mean values for each measure were calculated and
statistical analysis was performed by two-way ANOVA with
GraphPad (La Jolla, USA). Data are represented as mean 6 SEM.
Rotarod
Motor coordination and balance were evaluated in a rotarod
apparatus (Letica Scientific Instruments, Panlab, Barcelona,
Spain). Mice were placed on the rotarod at a constant speed
(5 rpm) for a maximum of 5 min, and at accelerated speed (4 to
40 rpm in 5 min) and the latency to fall was recorded. Mice were
allowed to perform four trials for each test and time point, with
15 min rest between trials. For analysis, the mean latency to fall off
the rotarod of 3–4 trials was used.
Footprint patterns analysis
The footprint test was used to compare the gait of mice injected
with vectors encoding shAtx3 with that of injected with shGFP
(control). Hind- and forefeet were coated with black and green
nontoxic paints, and the animals allowed walking along a 100-cm-
long, 10-cm-wide runaway (with 15-cm high walls) over a fresh
sheet of white paper. The footprint patterns were analyzed for (1)
stride length, corresponding to the average distance of forward
movement between each stride; (2) hind-base width and (3) front-
base width measured as the average distance between left and
right hind footprints, respectively, and (4) distance from left or
right front footprint/hind footprint overlap to measure uniformity
of step alternation. The distance between the center of the hind
footprint and the center of the preceding front footprint was
recorded over a sequence of six consecutive steps, excluding
footprints made at the beginning and end of the run. The same
operator made all footprints measurements blindly.
Open field analysis
For the assessment of mice explorative behavior, and locomotor
horizontal activity, mice were placed in a 50650 cm arena with
50 cm high walls and movement activity was recorded for 40 min
using Acti-Track System (Panlab, Barcelona, Spain). The collected
data was analyzed for the first 10 min, and for the last 30 minutes.
Histological processing
Tissue preparation. Tissue was prepared as previously
described (16). Slices throughout the entire cerebellum were
collected in superfrost plus microscope slides (Thermo Fisher
Scientific, U.S.A) and stored at 220uC before immunohistochem-
ical processing. For each animal the entire cerebellum was
collected into 12 slides with 8 coronal sections each, distant
240 mm from each other.
Immunohistochemical procedure
The immunohistochemical procedure was initiated with a
30 min dehydration at 37uC followed by a 30 min hydration in
0.1 PBS and 1 h blocking in a 0.3% triton in 0.1 PBS with 10%
normal goat serum both at room temperature (RT). The following
primary antibodies diluted in blocking solution with 0.1% triton
were used: mouse monoclonal anti-HA (InvivoGen, San Diego,
CA, USA; 1:1000; O/N, 4uC), and rabbit polyclonal anti-
Calbindin D-28K (Chemicon, Temecula, CA, USA; 1:1000, O/N,
4uC). Sections were then incubated in secondary antibody, goat-anti
rabbit and/or mouse conjugated to alexa 488 or 594 (Invitrogen) for
2 h/RT and then mounted in Fluorsave (Calbiochem, Germany)
with 49,69-diamidino-2-phenylindole (DAPI). Fluorescence images
were acquired with a Zeiss Axiovert 200 imaging microscope or
LSM Zeiss microscope for double staining experiments.
Fluorojade B staining
Cerebellar sections were stained with FluoroJade-B (Chemicon,
Temecula, CA), an anionic fluorescein derivative that stains
neurons undergoind degeneration. The sections were first washed
in water and then mounted on silanecoated glass slides,
dehydrated, and stained according to the supplier’s manual. All
photographs for comparison were taken under identical image
acquisition conditions and uniform adjustments of brightness and
contrast were made to all images.
Golgi staining
Golgi neurohistological staining was performed following a
modification of classical Golgi procedure described previously
[55].
Western blot
Mice cerebella were removed after a sodium pentobarbital
overdose, and incubated on ice in a radioimmunoprecipitation
assay-buffer solution (50 mM Tris HCl, pH 8, 150 nM NaCl, 1%
NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
sulphate) containing proteases inhibitors (Roche diagnostics
GmbH) followed by a 4 sec ultra-sound pulse (1 pulse/sec). Total
protein lysates were stored at 280uC, protein concentration was
determined with the Bradford protein assay (BioRad), and 20 mg
of protein extract was resolved in sodium dodecyl sulphate-
polyacrylamide gels (4% stacking and 8% running). The proteins
were transferred onto polyvinylidene difluoride membranes (GE
Healthcare) according to standard protocols. The immunobloting
procedure was performed as described previously [10] with the
respective primary antibody (1C2, 1:1000, Millipore), followed by
incubation wit the corresponding alkaline phosphatase-linked
secondary antibody. Bands were visualized with Enhanced
Chemifluorescence substrate (ECF, GE Healthcare) and chemi-
fluorescence imaging (VersaDoc Imaging System Model 3000,
Bio-Rad). Membranes were stripped using 0.1 M glycine pH 2.3
(30 min, room temperature) and reprobed with mouse monoclonal
anti-b-actin antibody (1:5000, Sigma), and anti-b-gal antibody
(1:5000, Cell Signaling). Densitometric analysis was carried out in
the same gel using Image J software (NIH, USA).
Quantitative analysis of HA aggregates
Quantification of HA positive inclusions was performed blindly
by scanning 4 coronal sections spread over the anterior-posterior
extent of the cerebellum of each animal (inter-section distance:
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240 mm), using a 206 objective on a Zeiss Axiovert 200 imaging
microscope and the image J acquisition and analysis software
(NIH, USA). For each coronal section, 8 fields covering the entire
cerebellar cortex were digitalized. The total number of HA
inclusions, and the number of Purkinje cells were counted, and the
average number of inclusions per 100 Purkinje cells was plotted.
Quantitative analysis of calbindin neuronal expression
Quantification of calbindin immunoreactivity was performed
blindly by scanning 4 coronal sections spread over the anterior-
posterior extent of the cerebellum (inter-section distance: 240 mm),
using a 406 objective on a Zeiss Axiovert 200 imaging
microscope. For each coronal section, 8 fields covering the entire
cerebellar cortex were digitalized. Optical densitometry analysis
was performed with Image J (NIH, USA). Values are represented
as the mean value of calbindin optical density per section 6 SEM.
Cresyl violet staining
Cerebellar sections were stained with cresyl violet for 2 minutes,
differentiated in acetate buffer pH 3.8 to 4 (2.72% sodium acetate
and 1.2% acetic acid; 1:4 v/v), dehydrated by passing twice
through ethanol and toluol solutions, and mounted with EukittH
(O. Kindler GmbH & CO. Freiburg, Germany).
Quantification of granular and molecular layers size
Quantification was made over 4 cresyl violet staining coronal
sections spread over the anterior-posterior extent of the cerebellum
in a blind fashion (inter-section distance: 200–300 mm), using a
206 objective. For each coronal section, 8 fields covering the
entire cerebellar cortex were digitalized. For each acquired field at
least 6 measurements were made blindly in the same region for all
animals, and results converted to mm using Image J software
(NIH).
Supporting Information
Figure S1 A) The transgene used to generate the Q69 transgenic
mouse model (Torashima et al., 2008) was isolated from the
human ataxin-3 gene with the polymorphism (GRC transition,
highlighted in blue) that is present in 70% of MJD patients
(Stevanin et al., 1995; Gaspar et al., 1996). B) The presence of this
polymorphism permitted the design of an allele-specific silencing
of mutant ataxin-3 (Alves et al., 2008), using shRNAs in a LV
backbone (with a separate cassette containing the lacZ reporter
gene). As control a shRNA targeting GFP in a LV was used. C)
There is no homology between mouse ataxin-3 and human ataxin-
3 in the region targeted by the silencing sequence, which means
that the shRNA used in this study was specific only to human
ataxin-3.
(TIF)
Figure S2 Intracerebellar injection of 6 ml (200.000 ng/ml) of
lentiviral vectors (LV) encoding for Green Fluorescent Protein
(GFP) in the cerebellar vermis of transgenic mice (P21–25)
mediates an extensive antero-posterior transduction of the
cerebellar cortex (n=8). This extensive transduction was observed
from the place of the injection and covered almost 60% of the area
of the cerebellar cortex, mainly in the molecular layer and in
Purkinje cells.
(TIF)
Figure S3 The intracerebellar injection of LV encoding for GFP
in the cerebellar vermis mediates an extensive transduction of the
cells in the cerebellar cortex, mainly the molecular layer cells (ML),
and the Purkinje layer cells (PCL).
(TIF)
Figure S4 Transgenic mice injected with LV encoding a short-
hairpin against GFP (shGFP) exhibit ataxin-3 aggregates (HA tag,
green) co-localizing with LacZ (red, white arrows); whereas
aggregates from mice injected with short-hairpins against mutant
ataxin-3 (shAtx3) do not co-localize. This indicates that the
shRNAs targeting mutant ataxin-3, but not the control shRNAs
targeting GFP, prevent the formation of ataxin-3 aggregates.
(TIF)
Figure S5 DARPP-32 staining revealed a preservation of
immunoreactivity in transgenic mice injected with LV encoding
shAtx3 (n=8) as compared to mice injected with shGFP (arrows,
n=8). The figure shows representative images that were
reproducible among the different groups of animals. Scale bar:
40 mm.
(TIF)
Figure S6 Behavior analysis of studied transgenic mice. A) Time
course of mice behavior tests: rotarod performance test, footprints
patterns analysis and activity box monitoring were assessed every 2
weeks post-injection until 10 weeks. B) Footprints patterns
quantitative analysis. Hindbase width measures of shGFP injected
mice (n=8) show a significantly greater distance between left and
right limb compared to shAtx3 injected mice (n=8), indicating a
higher deficit of coordination in control mice. *Statistical
significance (*P,0.05; ***P,0.001; 2-way ANOVA, Bonferonni
post-test). C) Locomotor horizontal activity of mice was tracked for
30 minutes (after a 10 minutes habituation period) and analyzed
for maximum velocity (cm/sec). Mice injected with shAtx3 (n=8)
revealed a significantly better locomotor activity than control mice
(shGFP, n=8), as shown by faster movement from 4 weeks post-
injection. *Statistical significance (*P,0.05; 2-way ANOVA,
Bonferonni post-test). D) Allele specific silencing of mutant
ataxin-3 improves exploratory activity. Analysis of the first
10 minutes in the cage at 10 weeks post-injection for one zone
(arena not divided) revealed significantly-increased traveled
distance in mice injected with shAtx3 (n=8) compared to mice
injected with shGFP (n=8).
(TIF)
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